Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer

Robert T O'Donnell; S. J. DeNardo; A. Yuan; S. Shen; Carol M Richman; Primo N Lara; I. J. Griffith; D. S. Goldstein; D. L. Kukis; G. S. Martinez; G. R. Mirick; Gerald L Denardo; Frederick J Meyers

Radioimmunotherapy with ¹¹¹In/⁹⁰Y-2IT-BAD-m170 for metastatic prostate cancer

Robert T O'Donnell, S. J. DeNardo, A. Yuan, S. Shen, Carol M Richman, Primo N Lara, I. J. Griffith, D. S. Goldstein, D. L. Kukis, G. S. Martinez, G. R. Mirick, Gerald L Denardo, Frederick J Meyers

Research output: Contribution to journal › Article

52 Scopus citations

Abstract

Purpose: Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer. The objectives of this Phase I study of ¹¹¹In-2IT-BAD-m170 (for imaging) and ⁹⁰Y-2IT-BAD-m170 (for therapy) were to determine the toxicity and maximum tolerated dose (MTD), the specificity for targeting metastatic prostate cancer, and the efficacy for palliation of pain. Experimental Design: M170 is a mouse monoclonal antibody that targets adenocarcinomas. Patients with adequate renal and liver function, rising prostate-specific antigen, and androgen-independent metastatic prostate cancer were eligible. After estimation of dosimetry and pharmacokinetics with ¹¹¹In-2IT-BAD-m170, a single dose of ⁹⁰Y-2IT-BAD-m170 (0.185, 0.370, 0.555, or 0.740 GBq/m²) was administered to cohorts of three patients. Pain was assessed objectively by questionnaires before and for 8 weeks after RIT; weekly prostate-specific antigen levels were obtained for 2 months after RIT. Results: The MTD of ⁹⁰Y-2IT-BAD-m170 was 0.740 GBq/m² for patients that had up to 10% of the axial skeleton involved with prostate cancer. Toxicity was almost exclusively confined to reversible myelosuppression. Metastatic prostate cancer was targeted by ¹¹¹In-2IT-BAD-m170 in all 17 patients. The mean radiation dose delivered to 39 bone and 18 nodal metastases by ⁹⁰Y-2IT-BAD-m170 was 10.5 Gy/GBq (range 2.8-25.1). Thirteen of 17 patients reported pain before ⁹⁰Y-2IT-BAD-m170; 7 of these 13 had a partial or complete resolution of pain that lasted an average of 4.3 weeks. Conclusions: This study determined the MTD of ¹¹¹In/ ⁹⁰Y-2IT-BAD-m170 in patients with metastatic prostate cancer. The drugs were well tolerated, targeted metastases, and temporarily palliated pain.

Original language	English (US)
Pages (from-to)	1561-1568
Number of pages	8
Journal	Clinical Cancer Research
Volume	7
Issue number	6
State	Published - 2001

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Radioimmunotherapy with <sup>111</sup>In/<sup>90</sup>Y-2IT-BAD-m170 for metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this

O'Donnell, R. T., DeNardo, S. J., Yuan, A., Shen, S., Richman, C. M., Lara, P. N., Griffith, I. J., Goldstein, D. S., Kukis, D. L., Martinez, G. S., Mirick, G. R., Denardo, G. L., & Meyers, F. J. (2001). Radioimmunotherapy with ¹¹¹In/⁹⁰Y-2IT-BAD-m170 for metastatic prostate cancer. Clinical Cancer Research, 7(6), 1561-1568.

Radioimmunotherapy with ¹¹¹In/⁹⁰Y-2IT-BAD-m170 for metastatic prostate cancer. / O'Donnell, Robert T; DeNardo, S. J.; Yuan, A.; Shen, S.; Richman, Carol M ; Lara, Primo N; Griffith, I. J.; Goldstein, D. S.; Kukis, D. L.; Martinez, G. S.; Mirick, G. R.; Denardo, Gerald L ; Meyers, Frederick J.

In: Clinical Cancer Research, Vol. 7, No. 6, 2001, p. 1561-1568.

Research output: Contribution to journal › Article

O'Donnell, Robert T ; DeNardo, S. J. ; Yuan, A. ; Shen, S. ; Richman, Carol M ; Lara, Primo N ; Griffith, I. J. ; Goldstein, D. S. ; Kukis, D. L. ; Martinez, G. S. ; Mirick, G. R. ; Denardo, Gerald L ; Meyers, Frederick J. / Radioimmunotherapy with ¹¹¹In/⁹⁰Y-2IT-BAD-m170 for metastatic prostate cancer. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 6. pp. 1561-1568.

@article{20f1df86679141258a8b21d6b6fbca41,

title = "Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer",

abstract = "Purpose: Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer. The objectives of this Phase I study of 111In-2IT-BAD-m170 (for imaging) and 90Y-2IT-BAD-m170 (for therapy) were to determine the toxicity and maximum tolerated dose (MTD), the specificity for targeting metastatic prostate cancer, and the efficacy for palliation of pain. Experimental Design: M170 is a mouse monoclonal antibody that targets adenocarcinomas. Patients with adequate renal and liver function, rising prostate-specific antigen, and androgen-independent metastatic prostate cancer were eligible. After estimation of dosimetry and pharmacokinetics with 111In-2IT-BAD-m170, a single dose of 90Y-2IT-BAD-m170 (0.185, 0.370, 0.555, or 0.740 GBq/m2) was administered to cohorts of three patients. Pain was assessed objectively by questionnaires before and for 8 weeks after RIT; weekly prostate-specific antigen levels were obtained for 2 months after RIT. Results: The MTD of 90Y-2IT-BAD-m170 was 0.740 GBq/m2 for patients that had up to 10% of the axial skeleton involved with prostate cancer. Toxicity was almost exclusively confined to reversible myelosuppression. Metastatic prostate cancer was targeted by 111In-2IT-BAD-m170 in all 17 patients. The mean radiation dose delivered to 39 bone and 18 nodal metastases by 90Y-2IT-BAD-m170 was 10.5 Gy/GBq (range 2.8-25.1). Thirteen of 17 patients reported pain before 90Y-2IT-BAD-m170; 7 of these 13 had a partial or complete resolution of pain that lasted an average of 4.3 weeks. Conclusions: This study determined the MTD of 111In/ 90Y-2IT-BAD-m170 in patients with metastatic prostate cancer. The drugs were well tolerated, targeted metastases, and temporarily palliated pain.",

author = "O'Donnell, {Robert T} and DeNardo, {S. J.} and A. Yuan and S. Shen and Richman, {Carol M} and Lara, {Primo N} and Griffith, {I. J.} and Goldstein, {D. S.} and Kukis, {D. L.} and Martinez, {G. S.} and Mirick, {G. R.} and Denardo, {Gerald L} and Meyers, {Frederick J}",

year = "2001",

language = "English (US)",

volume = "7",

pages = "1561--1568",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "6",

}

TY - JOUR

T1 - Radioimmunotherapy with 111In/90Y-2IT-BAD-m170 for metastatic prostate cancer

AU - O'Donnell, Robert T

AU - DeNardo, S. J.

AU - Yuan, A.

AU - Shen, S.

AU - Richman, Carol M

AU - Lara, Primo N

AU - Griffith, I. J.

AU - Goldstein, D. S.

AU - Kukis, D. L.

AU - Martinez, G. S.

AU - Mirick, G. R.

AU - Denardo, Gerald L

AU - Meyers, Frederick J

PY - 2001

Y1 - 2001

N2 - Purpose: Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer. The objectives of this Phase I study of 111In-2IT-BAD-m170 (for imaging) and 90Y-2IT-BAD-m170 (for therapy) were to determine the toxicity and maximum tolerated dose (MTD), the specificity for targeting metastatic prostate cancer, and the efficacy for palliation of pain. Experimental Design: M170 is a mouse monoclonal antibody that targets adenocarcinomas. Patients with adequate renal and liver function, rising prostate-specific antigen, and androgen-independent metastatic prostate cancer were eligible. After estimation of dosimetry and pharmacokinetics with 111In-2IT-BAD-m170, a single dose of 90Y-2IT-BAD-m170 (0.185, 0.370, 0.555, or 0.740 GBq/m2) was administered to cohorts of three patients. Pain was assessed objectively by questionnaires before and for 8 weeks after RIT; weekly prostate-specific antigen levels were obtained for 2 months after RIT. Results: The MTD of 90Y-2IT-BAD-m170 was 0.740 GBq/m2 for patients that had up to 10% of the axial skeleton involved with prostate cancer. Toxicity was almost exclusively confined to reversible myelosuppression. Metastatic prostate cancer was targeted by 111In-2IT-BAD-m170 in all 17 patients. The mean radiation dose delivered to 39 bone and 18 nodal metastases by 90Y-2IT-BAD-m170 was 10.5 Gy/GBq (range 2.8-25.1). Thirteen of 17 patients reported pain before 90Y-2IT-BAD-m170; 7 of these 13 had a partial or complete resolution of pain that lasted an average of 4.3 weeks. Conclusions: This study determined the MTD of 111In/ 90Y-2IT-BAD-m170 in patients with metastatic prostate cancer. The drugs were well tolerated, targeted metastases, and temporarily palliated pain.

AB - Purpose: Over 31,000 Americans die of androgen-independent metastatic prostate cancer each year. New strategies that do not involve hormonal manipulation but instead recognize the biochemical and molecular characteristics of prostate cancer are needed. Radioimmunotherapy (RIT) uses a tumor-specific monoclonal antibody to deliver systemic, targeted radiation to cancer. The objectives of this Phase I study of 111In-2IT-BAD-m170 (for imaging) and 90Y-2IT-BAD-m170 (for therapy) were to determine the toxicity and maximum tolerated dose (MTD), the specificity for targeting metastatic prostate cancer, and the efficacy for palliation of pain. Experimental Design: M170 is a mouse monoclonal antibody that targets adenocarcinomas. Patients with adequate renal and liver function, rising prostate-specific antigen, and androgen-independent metastatic prostate cancer were eligible. After estimation of dosimetry and pharmacokinetics with 111In-2IT-BAD-m170, a single dose of 90Y-2IT-BAD-m170 (0.185, 0.370, 0.555, or 0.740 GBq/m2) was administered to cohorts of three patients. Pain was assessed objectively by questionnaires before and for 8 weeks after RIT; weekly prostate-specific antigen levels were obtained for 2 months after RIT. Results: The MTD of 90Y-2IT-BAD-m170 was 0.740 GBq/m2 for patients that had up to 10% of the axial skeleton involved with prostate cancer. Toxicity was almost exclusively confined to reversible myelosuppression. Metastatic prostate cancer was targeted by 111In-2IT-BAD-m170 in all 17 patients. The mean radiation dose delivered to 39 bone and 18 nodal metastases by 90Y-2IT-BAD-m170 was 10.5 Gy/GBq (range 2.8-25.1). Thirteen of 17 patients reported pain before 90Y-2IT-BAD-m170; 7 of these 13 had a partial or complete resolution of pain that lasted an average of 4.3 weeks. Conclusions: This study determined the MTD of 111In/ 90Y-2IT-BAD-m170 in patients with metastatic prostate cancer. The drugs were well tolerated, targeted metastases, and temporarily palliated pain.

UR - http://www.scopus.com/inward/record.url?scp=0034895678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034895678&partnerID=8YFLogxK

M3 - Article

C2 - 11410491

AN - SCOPUS:0034895678

VL - 7

SP - 1561

EP - 1568

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -